J&J Wins EU Approval for ICOTYDE, First Targeted Oral Peptide for Plaque Psoriasis

Johnson & Johnson (JNJ) said the European Commission approved ICOTYDE, a once-daily oral treatment for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The decision, announced September 21, 2026, marks the first approval of a targeted oral peptide for the condition. The approval covers patients requiring systemic therapy and adds an oral option to the company's dermatology portfolio. J&J did not disclose pricing or launch timing for the European market. ICOTYDE's clearance follows regulatory review by the European Commission and positions the treatment against existing injectable biologics and conventional oral systemic therapies in the psoriasis segment.